KCNK5 and autoimmune disease: Therefore, the development of small molecule K2P5.1 modulators may represent therapeutic and/or preventative strategies for the treatment of inflammatory and autoimmune disorders and cancer, and the establishment of a novel high-throughput screening system to detect these modulators currently required (Bagriantsev et al., 2013).